ArticleScientific reports2026
Construction of a homologous targeting exosome-based drug delivery system for colorectal cancer and evaluation of its anti-tumor efficacy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Small Extracellular Vesicles for Colon-Targeted Delivery: Microenvironment-Responsive Design, Therapeutic Mechanisms, and Clinical Translation.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aimed to use the homologous targeting property of tumor-derived exosomes to construct a novel drug delivery system for SN38 and assess its enhanced therapeutic potential in colorectal cancer models. Exosomes were isolated from HT29 colorectal cancer cells (HT29-EXO) and NCM460 normal intestinal epithelial cells (NCM460-EXO) using differential ultracentrifugation, followed by characterization via nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and Western blotting (WB). The chemotherapeutic drug SN38 was subsequently loaded into the exosomes via electroporation. The homologous targeting capability of HT29-EXO was validated through both in vitro cell co-culture studies and in vivo live imaging. Finally, the antitumor efficacy of the drug-loaded exosomes (HT29-EXO+SN38) was systematically evaluated using CCK-8 cell viability assays, flow cytometry-based apoptosis analysis, and a subcutaneous xenograft mouse model. This study conclusively demonstrates the superior homologous targeting of HT29-derived exosomes, showing 1.5-fold higher in vitro binding affinity and 2-fold greater in vivo tumor accumulation compared to control exosomes (NCM460-EXO). The therapeutic formulation HT29-EXO+SN38 proved significantly more effective. In vitro, it exhibited the strongest growth inhibition, reducing cell viability to 35.79%. Flow cytometry revealed that while total apoptosis rates were comparable, HT29-EXO+SN38 induced the highest rate of late apoptosis (41.57%, p < 0.001 vs. others). These results were corroborated in vivo, where the HT29-EXO+SN38 group showed the most potent efficacy, achieving the lowest final tumor weight (182.0 ± 36.33 mg) and smallest volume (103.1 ± 36.8 mm³), with significant differences versus all other groups (p < 0.05). Utilizing homologous tumor-derived exosomes as drug carriers enhances tumor inhibition by their superior targeting of parental cells and tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.